In vivo imaging of inflammation and oxidative stress in a nonhuman primate model of cardiac sympathetic neurodegeneration
Authors:
Open Access
- 13 July 2018
- journal article
- research article
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 4 (1) , 1-12
Abstract
Loss of cardiac postganglionic sympathetic innervation is a characteristic pathology of Parkinson’s disease (PD). It progresses over time independently of motor symptoms and is not responsive to typical anti-parkinsonian therapies. Cardiac sympathetic neurodegeneration can be mimicked in animals using systemic dosing of the neurotoxin 6-hydroxydopamine (6-OHDA). As in PD, 6-OHDA-induced neuronal loss is associated with increased inflammation and oxidative stress. To assess the feasibility of detecting changes over time in cardiac catecholaminergic innervation, inflammation, and oxidative stress, myocardial positron emission tomography with the radioligands [11C]meta-hydroxyephedrine (MHED), [11C]PBR28 (PBR28), and [61Cu]diacetyl-bis(N(4))-methylthiosemicarbazone (ATSM) was performed in 6-OHDA-intoxicated adult, male rhesus macaques (n = 10; 50 mg/kg i.v.). The peroxisome proliferator-activated receptor gamma (PPARγ) agonist pioglitazone, which is known to have anti-inflammatory and anti-oxidative stress properties, was administered to five animals (5 mg/kg, PO); the other five were placebo-treated. One week after 6-OHDA, cardiac MHED uptake was significantly reduced in both groups (placebo, 86% decrease; pioglitazone, 82%); PBR28 and ATSM uptake increased in both groups but were attenuated in pioglitazone-treated animals (PBR28 Treatment × Level ANOVAp < 0.002; ATSM Mann–Whitneyp = 0.032). At 12 weeks, partial recovery of MHED uptake was significantly greater in the pioglitazone-treated group, dependent on left ventricle circumferential region and axial level (Treatment × Region × Level ANOVAp = 0.034); 12-week MHED uptake significantly correlated with tyrosine hydroxylase immunoreactivity across cardiac anatomy (p < 0.000002). PBR28 and ATSM uptake returned to baseline levels by 12 weeks. These radioligands thus hold potential as in vivo biomarkers of mechanisms of cardiac neurodegeneration and neuroprotection.Keywords
This publication has 60 references indexed in Scilit:
- Oxidative stress and Parkinson’s diseaseFrontiers in Neuroanatomy, 2015
- Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's diseaseNeurobiology of Disease, 2014
- Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAsFrontiers in Psychology, 2013
- Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PETNuclear Medicine and Biology, 2011
- Fully automated synthesis and initial PET evaluation of [11C]PBR28Bioorganic & Medicinal Chemistry Letters, 2009
- Orthostatic hypotension, balance and falls in Parkinson's diseaseMovement Disorders, 2009
- PPARγ Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory PropertiesCell Metabolism, 2007
- Reduced cardiac 123 I-MIBG scintigraphy in idiopathic REM sleep behavior disorderNeurology, 2006
- Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's diseaseMovement Disorders, 2003
- Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential.1997